

a¹ 1. (Amended) A method of treating a disease condition in a subject
[by ~~vasodilation or vasorelaxation~~] comprising:

~~selecting a subject; and~~

B
B administering a mixture of L-arginine and an inhibitor of Hmg-
CoA reductase; *to said subject*

~~obtaining periodic indicators of vasorelaxations for the subject;~~

~~and~~

~~continuing administration of the mixture until a desirable state
of vasorelaxation is obtained];~~

a² 3. (Amended) The method of claim 1, wherein said disease
condition is hypertension, hypertensive heart disease, coronary heart disease,
cardiovascular disease, cerebrovascular disease, and renovascular disease.

Please cancel claims 7-11 without prejudice to presentation in
this or a later filed case.

Please amend claim 12 as follows:

a³ 12. (Amended) A therapeutic mixture of [an agonist of NOS and] a
substrate of NOS and an inhibitor of Hmg-CoA reductase.

Please cancel claims 14-15.

Please amend claims 16-18 as follows:

a⁴ 16. (Amended) A method of stimulating Nitric Oxide Synthase [to
produce nitric oxide], said method comprising:

24 cont
administering L-arginine and an Hmg-CoA reductase inhibitor
[agonist of nitric oxide synthase to a subject having a nitric oxide synthase receptor
site, said agonist being different than L-arginine and being selected from the group
consisting of:

lovastatin;

pravastatin;

simvastatin;

fluvastatin;

dalvastatin;

compactin;

HR-780;

BMY 22,089;

BMY 22,566;

SQ 33,600;

GR 95,030; or

CI 981;

stimulating said nitric oxide synthase to a desirable level with
said agonist of nitric oxide synthase].

17. (Amended) The method of claim 16, wherein said L-arginine is

in excess to said [agonist] Hmg-CoA reductase inhibitor.

18. (Amended) The method of claim 16, wherein a therapeutically effective [amounts] amount of said L-arginine is combined with a therapeutically effective [amounts] amount of said [agonist] Hmg-CoA reductase inhibitor prior to [administering to the patient] said administration.

Please add the following new claims:

19. (New) The method of claim 1, further including the step of obtaining periodic indicators of vasorelaxations for the subject; and continuing administration of the mixture until a desirable state of vasorelaxation is obtained.

20. (New) The method of claim 1 wherein said inhibitor of Hmg-CoA reductase is atorvastatin.

21. (New) The method of claim 1 wherein said inhibitor of Hmg-CoA reductase is cerivastatin.

22. (New) The therapeutic mixture of claim 12, wherein said inhibitor of Hmg-CoA reductase is an agonist of NOS.

23. (New) The therapeutic mixture of claim 12, wherein said inhibitor of Hmg-CoA reductase is atorvastatin.

24. (New) The therapeutic mixture of claim 13, wherein said inhibitor of Hmg-CoA reductase is atorvastatin and said biological equivalent of L-arginine is L-arginine.

25. (New) The therapeutic mixture of claim 12, wherein said inhibitor of Hmg-CoA reductase is cerivastatin.

26. (New) The therapeutic mixture of claim 13, wherein said